Drug intelligence / Profile preview

JNJ-64417184

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-64417184 is an investigational small molecule antiviral drug developed for the treatment of respiratory syncytial virus (RSV) infection. It acts as a non-nucleoside polymerase inhibitor, targeting the viral RNA-dependent RNA polymerase and thereby inhibiting viral protein production and replication. The drug is administered orally in tablet form and has been evaluated in multiple phase 1 clinical studies to assess its safety, tolerability, pharmacokinetics, and antiviral activity in healthy volunteers. Development has primarily focused on RSV infection, particularly for populations at risk such as infants and the elderly[1][3][5][6].

Other names: JNJ 64417184JNJ64417184JNJ-64417184

Targets

RSV L (Respiratory syncytial virus L protein)

Beyond the preview

Go deeper on JNJ-64417184.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-64417184.

Explore the full profile